Trial Search Results

Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.

The main purpose of this study is to learn how effective a drug called nilotinib (Tasigna®) is treating children that have either newly diagnosed Ph+CML CP or Ph+CML CP or AP that has not improved or has shown to make you too sick with a treatment called imatinib (Gleevec®/Glivec®) or dasatinib (Sprycel®).

Stanford is currently not accepting patients for this trial.

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Cancer Clinical Trials Office
650-498-7061
Not Recruiting